Efficacy of Silexan in subthreshold anxiety: meta-analysis of randomised, placebo-controlled trials

[1]  J. Higgins,et al.  Cochrane Handbook for Systematic Reviews of Interventions , 2010, International Coaching Psychology Review.

[2]  N. Zareifopoulos,et al.  Efficacy and tolerability of vilazodone for the acute treatment of generalized anxiety disorder: A meta-analysis. , 2017, Asian journal of psychiatry.

[3]  H. Möller,et al.  Silexan does not cause withdrawal symptoms even when abruptly discontinued , 2017, International journal of psychiatry in clinical practice.

[4]  Q. Cordeiro,et al.  Lavender Oil Preparation (Silexan) for Treating Anxiety: An Updated Meta-Analysis , 2017, Journal of clinical psychopharmacology.

[5]  Richard D Riley,et al.  Meta‐analysis using individual participant data: one‐stage and two‐stage approaches, and why they may differ , 2016, Statistics in medicine.

[6]  D. Baldwin,et al.  Efficacy of escitalopram in the treatment of social anxiety disorder: A meta-analysis versus placebo , 2016, European Neuropsychopharmacology.

[7]  H. Volz,et al.  Efficacy of Silexan in mixed anxiety–depression – A randomized, placebo-controlled trial , 2016, European Neuropsychopharmacology.

[8]  S. Kasper,et al.  Efficacy of orally administered Silexan in patients with anxiety-related restlessness and disturbed sleep – A randomized, placebo-controlled trial , 2015, European Neuropsychopharmacology.

[9]  C. Taylor,et al.  Classification models for subthreshold generalized anxiety disorder in a college population: Implications for prevention. , 2015, Journal of anxiety disorders.

[10]  W. Dimpfel,et al.  Cerebral Bioavailability of Silexan— A Quantitative EEG Study in Healthy Volunteers , 2015 .

[11]  A. Quante.  Akute pharmakologische Therapieoptionen von ängstlicher Symptomatik bei Patienten mit Depression , 2015 .

[12]  S. Kasper,et al.  Effects of Silexan on the Serotonin-1A Receptor and Microstructure of the Human Brain: A Randomized, Placebo-Controlled, Double-Blind, Cross-Over Study with Molecular and Structural Neuroimaging , 2015, The international journal of neuropsychopharmacology.

[13]  A. Dienel,et al.  No Interacting Influence of Lavender Oil Preparation Silexan on Oral Contraception Using an Ethinyl Estradiol/Levonorgestrel Combination , 2014, Drugs in R&D.

[14]  H. Möller,et al.  Lavender oil preparation Silexan is effective in generalized anxiety disorder--a randomized, double-blind comparison to placebo and paroxetine. , 2014, The international journal of neuropsychopharmacology.

[15]  G. Dobos,et al.  The prevalence and burden of subthreshold generalized anxiety disorder: a systematic review , 2014, BMC Psychiatry.

[16]  S. Kasper.  An orally administered lavandula oil preparation (Silexan) for anxiety disorder and related conditions: an evidence based review , 2013, International journal of psychiatry in clinical practice.

[17]  N. Klugbauer,et al.  Lavender Oil-Potent Anxiolytic Properties via Modulating Voltage Dependent Calcium Channels , 2013, PloS one.

[18]  B. Penninx,et al.  COURSE AND RISK FACTORS OF FUNCTIONAL IMPAIRMENT IN SUBTHRESHOLD DEPRESSION AND ANXIETY , 2013, Depression and anxiety.

[19]  Vikas Kumar.  Characterization of anxiolytic and neuropharmacological activities of Silexan , 2013, Wiener Medizinische Wochenschrift.

[20]  A. Dienel,et al.  Phase II trial on the effects of Silexan in patients with neurasthenia, post-traumatic stress disorder or somatization disorder. , 2012, Phytomedicine : international journal of phytotherapy and phytopharmacology.

[21]  H. Möller,et al.  Guidelines for the pharmacological treatment of anxiety disorders, obsessive–compulsive disorder and posttraumatic stress disorder in primary care , 2012, International journal of psychiatry in clinical practice.

[22]  Russell A Poldrack,et al.  Human anterior and posterior hippocampus respond distinctly to state and trait anxiety. , 2012, Emotion.

[23]  J. Sterne,et al.  The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials , 2011, BMJ : British Medical Journal.

[24]  H. Polarz,et al.  Silexan und Narkose , 2011, Der Anaesthesist.

[25]  S. Kertz,et al.  Human and Economic Burden of GAD, Subthreshold GAD, and Worry in a Primary Care Sample , 2011, Journal of Clinical Psychology in Medical Settings.

[26]  P. Cuijpers,et al.  Psychiatric history and subthreshold symptoms as predictors of the occurrence of depressive or anxiety disorder within 2 years. , 2011, The British journal of psychiatry : the journal of mental science.

[27]  J. Higgins.  Cochrane handbook for systematic reviews of interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration , 2011 .

[28]  S. Leucht,et al.  Second-generation antipsychotics for anxiety disorders. , 2010, The Cochrane database of systematic reviews.

[29]  H. Möller,et al.  Efficacy and safety of silexan, a new, orally administered lavender oil preparation, in subthreshold anxiety disorder – evidence from clinical trials , 2010, Wiener Medizinische Wochenschrift.

[30]  H. Möller,et al.  Silexan, an orally administered Lavandula oil preparation, is effective in the treatment of ‘subsyndromal’ anxiety disorder: a randomized, double-blind, placebo controlled trial , 2010, International clinical psychopharmacology.

[31]  R. Riley,et al.  Meta-analysis of individual participant data: rationale, conduct, and reporting , 2010, BMJ : British Medical Journal.

[32]  H. Woelk,et al.  A multi-center, double-blind, randomised study of the Lavender oil preparation Silexan in comparison to Lorazepam for generalized anxiety disorder. , 2010, Phytomedicine : international journal of phytotherapy and phytopharmacology.

[33]  T. Brown,et al.  Differentiating Generalized Anxiety Disorder From Anxiety Disorder Not Otherwise Specified , 2009, The Journal of nervous and mental disease.

[34]  W. Setzer.  Essential Oils and Anxiolytic Aromatherapy , 2009, Natural product communications.

[35]  J. Davidson,et al.  An effect-size analysis of pharmacologic treatments for generalized anxiety disorder , 2007, Journal of psychopharmacology.

[36]  B. Bandelow.  Defining Response and Remission in Anxiety Disorders: Toward an Integrated Approach , 2006, CNS Spectrums.

[37]  C. Magai,et al.  The prevalence of anxiety and associated factors in a multiracial sample of older adults. , 2006, Psychiatric services.

[38]  D. Dozois,et al.  Gaps in accessing treatment for anxiety and depression: challenges for the delivery of care. , 2004, Clinical psychology review.

[39]  Cheryl A Flynn,et al.  Antidepressants for generalized anxiety disorder. , 2003, American family physician.

[40]  G. Diefenbach,et al.  'Minor GAD': characteristics of subsyndromal GAD in older adults. , 2003, Behaviour research and therapy.

[41]  Hans-Ulrich Wittchen,et al.  Generalized anxiety disorder: prevalence, burden, and cost to society , 2002, Depression and anxiety.

[42]  J. Ferguson.  SSRI Antidepressant Medications: Adverse Effects and Tolerability. , 2001, Primary care companion to the Journal of clinical psychiatry.

[43]  C. Shapiro,et al.  Differentiating DSM-IV Anxiety and Depressive Disorders in the General Population: Comorbidity and Treatment Consequences , 2000, Canadian journal of psychiatry. Revue canadienne de psychiatrie.

[44]  F. Simons.  H1-Receptor Antagonists , 1994, Drug safety.

[45]  I. Heuser,et al.  The Hamilton Anxiety Scale: reliability, validity and sensitivity to change in anxiety and depressive disorders. , 1988, Journal of affective disorders.